keyword
MENU ▼
Read by QxMD icon Read
search

tocilizumab

keyword
https://www.readbyqxmd.com/read/29149289/rheumatoid-arthritis-patients-treated-in-trial-and-real-world-settings-comparison-of-randomized-trials-with-registries
#1
Gablu Kilcher, Noemi Hummel, Eva M Didden, Matthias Egger, Stephan Reichenbach
Objective: To investigate whether patients with RA enrolled in randomized controlled trials (RCTs) and observational studies may differ in terms of characteristics that could modify treatment effects, leading to an efficacy-effectiveness gap. Methods: We conducted systematic literature reviews to identify RCTs and observational studies with RA, treated with rituximab, tocilizumab or etanercept. We extracted baseline characteristics and compared the data of RCTs and observational studies using fixed-effects meta-analyses for the RCTs and random-effects meta-analyses for the observational studies...
November 14, 2017: Rheumatology
https://www.readbyqxmd.com/read/29146040/-effectiveness-therapeutic-maintenance-and-reasons-for-stopping-tocilizumab-tcz-a-retrospective-and-monocentric-study-in-88%C3%A2-patients-followed-for-rheumatoid-arthritis-ra-at-the-reims-university-hospital
#2
Clément Chopin, Loïc Pauvelle, Sarah Jaulerry, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon
OBJECTIVE: Study the therapeutic maintenance, efficacy and reasons for tocilizumab stop in daily practice. PATIENTS AND METHODS: A monocentric, retrospective study of patients treated for rheumatoid arthritis who received at least one TCZ infusion between January 2009 and December 2015. Therapeutic maintenance was evaluated using the Kaplan-Meier method. The efficacy of TCZ was measured by DAS28 and the EULAR response. Reasons for stopping and new treatment lines were also collected...
October 18, 2017: Thérapie
https://www.readbyqxmd.com/read/29146018/biological-treatments-in-giant-cell-arteritis-takayasu-arteritis
#3
Maxime Samson, Georgina Espígol-Frigolé, Nekane Terrades-García, Sergio Prieto-González, Marc Corbera-Bellalta, Roser Alba-Rovira, José Hernández-Rodríguez, Sylvain Audia, Bernard Bonnotte, Maria C Cid
Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main large vessel vasculitides. They share some similarities regarding their clinical, radiological and histological presentations but some pathogenic processes in GCA and TAK are activated differently, thus explaining their different sensitivity to biological therapies. The treatment of GCA and TAK essentially relies on glucocorticoids. However, thanks to major progress in our understanding of their pathogenesis, the role of biological therapies in the treatment of these two vasculitides is expanding, especially in relapsing or refractory diseases...
November 13, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29143933/long-term-effectiveness-of-tocilizumab-in-patients-with-rheumatoid-arthritis-stratified-by-number-of-previous-treatment-failures-with-biologic-agents-results-from-the-german-rabbit-cohort
#4
Lisa Baganz, Adrian Richter, Jörn Kekow, Arnold Bussmann, Andreas Krause, Carsten Stille, Joachim Listing, Angela Zink, Anja Strangfeld
In Germany, Tocilizumab (TCZ) is used for the treatment of rheumatoid arthritis both in biologic-naïve patients and those with previous failures of biologic disease-modifying antirheumatic drugs (bDMARDs). The long-term effectiveness and retention rates of TCZ in patients with different numbers of prior bDMARD failures has rarely been investigated. We included 885 RA patients in the analyses, enrolled with the start of TCZ between 2009 and 2015 in the German biologics register RABBIT. Patients were stratified according to prior bDMARD failures: no prior bDMARD or 1, 2 or ≥ 3 bDMARD failures...
November 16, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29141313/-tocilizumab-for-refractory-systemic-juvenile-idiopathic-arthritis
#5
J M Lai, F Q Wu, Z X Zhou, M Kang, X L Huang, G X Su, S N Li, J Zhu, X N Wang
Objective: To evaluate the efficacy and side effects of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Method: In this prospective self case-control study, the children diagnosed with refractory systemic juvenile idiopathic arthritis admitted to Department of Rheumatism and Immunology of Children's Hospital Affiliated to Capital Institute of Pediatrics from December 2013 to June 2016 were enrolled and information before and after treatment of tocilizumab was analyzed. The tocilizumab was introvenously guttae in a dose of 8-12 mg/kg every 2 weeks...
November 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/29131037/paradoxical-reactions-anti-tumor-necrosis-factor-alpha-agents-ustekinumab-secukinumab-ixekizumab-and-others
#6
Lluís Puig
Paradoxical reactions during treatment with a biologic agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition, which usually remains under control (even though there may be a change in morphology or phenotype). Paradoxical reactions were initially described as isolated case reports or case series in patients treated with anti-tumor necrosis factor (TNF) α agents, first in inflammatory rheumatic diseases, later in psoriasis and inflammatory bowel disease...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#7
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29126664/fatal-dress-syndrome-under-tocilizumab-treatment-for-seronegative-polyarthritis
#8
Benoit Ben Said, Mathieu Gerfaud-Valentin, Pascal Seve
No abstract text is available yet for this article.
November 7, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29122286/integrated-microreactor-for-enzymatic-reaction-automation-an-easy-step-toward-the-quality-control-of-monoclonal-antibodies
#9
Yoann Ladner, Silvia Mas, Gaelle Coussot, Killian Bartley, Jérôme Montels, Jacques Morel, Catherine Perrin
The main purpose of the present work is to provide a fully integrated miniaturized electrophoretic methodology in order to facilitate the quality control of monoclonal antibodies (mAbs). This methodology called D-PES, which stands for Diffusion-mediated Proteolysis combined with an Electrophoretic Separation, permits to perform subsequently mAb tryptic digestion and electrophoresis separation of proteolysis products in an automated manner. Tryptic digestion conditions were optimized regarding the influence of enzyme concentration and incubation time in order to achieve similar enzymatic digestion efficiency to that obtained with the classical methodology (off-line)...
October 27, 2017: Journal of Chromatography. A
https://www.readbyqxmd.com/read/29117496/coronary-artery-aneurysm-in-tocilizumab-treated-children-with-kawasaki-s-disease
#10
LETTER
Tomo Nozawa, Tomoyuki Imagawa, Shuichi Ito
New England Journal of Medicine, Volume 377, Issue 19, Page 1894-1896, November 2017.
November 9, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29110911/blau-syndrome-with-good-reponses-to-tocilizumab-a-case-report-and-focused-literature-review
#11
Li Lu, Min Shen, Dongbin Jiang, Yanmin Li, Xiaolong Zheng, Yao Li, Zhixun Li, Leilei Zhang, Jungen Tang, Yanke Guo, Shengyun Liu, Zhaohui Zheng, Guanmin Gao, Quancheng Kan
OBJECTIVES: Blau syndrome (BS), a rare auto-inflammatory granulomatous disease, is a progressive disorder. Usually the maintenance dose of glucocorticoid may not be tapered below 15 mg per day while immunosuppressives is used. There has been some experience with biologic agents in refractory BS patients. The objective of this study is to describe the case of a BS patient benefiting from Tocilizumab, a humanized monoclonal antibody against interleukin 6 receptor. METHODS: We report the first Chinese patient with BS who was resistant to currently available therapies but had rapid quiescence after using Tocilizumab...
September 25, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29095992/radiographic-joint-damage-in-early-rheumatoid-arthritis-patients-comparing-tocilizumab-and-methotrexate-based-treat-to-target-strategies
#12
Xavier M Teitsma, Johannes W G Jacobs, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Floris P J G Lafeber, Johannes W J Bijlsma
Objective: To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands in the U-Act-Early trial. Methods: In this trial, 317 newly diagnosed DMARD-naïve RA patients initiated randomly tocilizumab, or step-up MTX or a combination of the two. Radiographs were scored at baseline and after 52 and 104 weeks using the Sharp-van der Heijde erosion and JSN score. Between the strategy arms, changes from baseline and the proportions of patients without radiographic progression (change from baseline ≤0) were compared...
October 31, 2017: Rheumatology
https://www.readbyqxmd.com/read/29094311/tocilizumab-a-review-in-rheumatoid-arthritis
#13
Lesley J Scott
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra(®)), an IL-6 receptor antagonist, are approved (± methotrexate) in numerous countries throughout the world, for the treatment of adults with moderate to severe active rheumatoid arthritis (RA). Extensive clinical experience has firmly established the short- and long-term efficacy and safety of tocilizumab [monotherapy or in combination with conventional synthetic DMARDs (csDMARDs)] in adults with early-stage and longer-duration established RA...
November 2017: Drugs
https://www.readbyqxmd.com/read/29093249/-clinical-effect-of-tocilizumab-on-patients-with-severe-active-rheumatoid-arthritis
#14
Suqing Xu, Xi Xie, Mengshi Tang, Jinwei Chen, Jing Tian, Jinfeng Du, Ni Mao, Yiming Liu, Shu Li, Meiyan Song, Jiesheng Gao, Guanghui Ling, Fen Li
To evaluate therapeutic effects and adverse reactions of tocilizumab on patients with severe active rheumatoid arthritis (RA).
 Methods: Twelve patients with severe refractory RA were treated with tocilizumab. The clinical and laboratory indices and the side effects were recorded after treatment.
 Results: The clinical and laboratory indices and the disease activity score 28 (DAS28) were observed in all patients, which were significantly improved after TCZ therapy (P<0.05), and no obvious adverse reactions were found...
October 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/29090685/a-randomized-double-blind-placebo-controlled-clinical-trial-of-tocilizumab-an-interleukin-6-receptor-antibody-for-residual-symptoms-in-schizophrenia
#15
Ragy R Girgis, Adam Ciarleglio, Tse Choo, Gregory Haynes, Joan M Bathon, Serge Cremers, Joshua T Kantrowitz, Jeffrey A Lieberman, Alan S Brown
Evidence from preclinical, epidemiological, and human studies indicates that inflammation, and in particular elevated IL-6 activity, may be related to clinical manifestations and pathophysiology of schizophrenia. Furthermore, studies in preclinical models suggest that decreasing IL-6 activity may mitigate or reverse some of these deficits. The purpose of this trial was to test whether an IL-6 receptor antibody, tocilizumab, would improve residual positive and negative symptoms and cognitive deficits in schizophrenia...
November 1, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29079714/tocilizumab-for-the-treatment-of-slc29a3-mutation-positive-phid-syndrome
#16
Nadia K Rafiq, Khalid Hussain, Paul A Brogan
Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is associated with recessive mutations in SLC29A3, encoding the equilibrative nucleoside transporter hENT3 expressed in mitochondria, causing PHID and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy-plus syndrome. Autoinflammation is increasingly recognized in these syndromes. We previously reported a 16-year-old girl with PHID syndrome associated with severe autoinflammation that was recalcitrant to interleukin-1 and tumor necrosis factor-α blockade...
November 2017: Pediatrics
https://www.readbyqxmd.com/read/29077971/tocilizumab-as-a-potential-therapeutic-option-for-children-with-severe-refractory-juvenile-localized-scleroderma
#17
Hanna Lythgoe, Eileen Baildam, Michael W Beresford, Gavin Cleary, Liza J McCann, Clare E Pain
No abstract text is available yet for this article.
October 25, 2017: Rheumatology
https://www.readbyqxmd.com/read/29077900/patient-acceptable-symptom-state-in-scleroderma-results-from-the-tocilizumab-compared-with-placebo-trial-in-active-diffuse-cutaneous-systemic-sclerosis
#18
Michael B Arnold, Dinesh Khanna, Christopher P Denton, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Helen Spotswood, Laura Burke, Jeffrey Siegel, Angelika Jahreis, Daniel E Furst, Janet E Pope
Objectives: Patient acceptable symptom state (PASS) as an absolute state of well-being has shown promise as an outcome measure in many rheumatologic conditions. We aimed to assess whether PASS may be effective in active diffuse cutaneous SSc differentiating active from placebo. Methods: Data from the phase 2 Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (faSScinate) trial were used, which compared tocilizumab (TCZ) vs placebo over 48 weeks followed by an open-label TCZ period to 96 weeks...
October 25, 2017: Rheumatology
https://www.readbyqxmd.com/read/29076142/donor-derived-cd19-targeted-t-cell-infusion-induces-minimal-residual-disease-negative-remission-in-relapsed-b-cell-acute-lymphoblastic-leukaemia-with-no-response-to-donor-lymphocyte-infusions-after-haploidentical-haematopoietic-stem-cell-transplantation
#19
Yuhong Chen, Yifei Cheng, Pan Suo, Chenhua Yan, Yu Wang, Yao Chen, Wei Han, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Lungji Chang, Lei Xiao, Xiaojun Huang
Relapse is a common cause of failure in patients with B-cell acute lymphoblastic leukaemia (B-ALL) after haploidentical haematopoietic stem cell transplantation (haplo-HSCT), and non-responders to donor lymphoblastic infusion after HSCT have a very poor prognosis. Although donor-derived CD19-directed chimeric antigen receptor-modified (CAR) T cells can potentially cure leukaemia, their effectiveness and safety have not been confirmed in relapsed B-ALL cases after haplo-HSCT. Between January 2015 and January 2017, two and four patients each received one and two infusions of CAR T cells from haplo-HSCT donors...
October 26, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29069471/serious-infusion-related-reaction-after-rituximab-abatacept-and-tocilizumab-in-rheumatoid-arthritis-prospective-registry-data
#20
Jean-Hugues Salmon, Jeanne-Marie Perotin, Jacques Morel, Moustapha Dramé, Alain Cantagrel, Liana Euller Ziegler, Philippe Ravaud, Jean Sibilia, Isabelle Pane, Xavier Mariette, Jacques-Eric Gottenberg
Objective: The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics. Methods: We analysed data from three independent prospective registers, namely autoimmunity and rituximab, Orencia (abatacept) and RA (ORA) and Registry RoAcTEmra (tocilizumab), promoted by the French Society of Rheumatology and including patients with RA. SIRRs were defined by an occurrence during or within 24 h of an infusion and requiring discontinuation of treatment...
October 23, 2017: Rheumatology
keyword
keyword
5841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"